New human clinical trial proves arginine, an amino acid, can modify plaque formation on teeth, thereby protecting ...
A new drug combination shows unexpected synergy against liver fibrosis. A new study reveals that using two drugs together ...
The utilization of biodegradable biomaterials as a therapeutic modality for musculoskeletal tissue regeneration has emerged as a promising avenue for ...
The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...
FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Approval from HREC for Phase 1/2 Diabetic Foot Ulcer Trial In ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
AZoLifeSciences on MSN
Turning human fat into insulin-producing organoids that reverse diabetes
By preserving fat tissue architecture, researchers created organoids that restore insulin function, paving the way for ...
Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
Engitix plans to use the funds for preclinical development across its pipeline in solid tumors and fibrosis, and to expand ...
When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.
"After a review of BIASURGE®, Vizient’s client-led council agreed this technology offers a unique benefit over other products ...
Cathepsin B belongs to a family of lysosomal cysteine proteases (enzymes that break down proteins) present inside the cell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback